Stage IIIA-N2 NSCLC: A review of its treatment approaches and future developments

Lung Cancer

Volumn 65, Issue 3, 2009, Pages 257-267

  van Meerbeeck, Jan P ^a   Surmont, Veerle F M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemotherapy; Combined modality; N2 disease; Non small cell lung cancer; Radiotherapy; Stage IIIA; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; GEFITINIB; MITOMYCIN C; PACLITAXEL; PLACEBO; VINCA ALKALOID; VINDESINE;

ALGORITHM; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DRUG THERAPY; GUIDELINES AS TOPIC; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; NEOPLASM STAGING; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 66849138346     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.02.007     Document Type: Review

References (102)

1. Mountain C.F. The international system for staging lung cancer. Chest 111 (1997) 1710-1717
2. Mountain C.F. A new international staging system for lung cancer. Chest 89 4 Suppl. (1986) 225S-233S
3. Goldstraw P., Crowley J.J., Chansky K., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2 (2007) 705-714
4. Ruckdeschel J.C. Combined modality therapy of non-small cell lung cancer. Semin Oncol 24 (1997) 429-439
5. Andre F., Grunenwald D., Pignon J.P., et al. Survival of patients with resected N2 non-small cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18 (2000) 2981-2989
6. Robinson L.A., Ruckdeschel J.C., Wagner H., and Stevens C.W. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (2007) 243-265
7. Goldstraw P., Mannam G.C., Kaplan D.K., and Michail P. Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 107 January (1) (1994) 19-27
8. De Leyn P., Schoonooghe P., Deneffe G., et al. Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal nodes (N2 disease). Eur J Cardiothorac Surg 10 (1996) 649-654
9. Gonzalez S., Serra M., Cirera L., et al. Routine positron emission tomography (PET) and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer (NSCLC). J Clin Oncol (2006) ASCO Annual Meeting Proceedings Part I. 2006; 24 No. 18S: 7031
10. Cerfolio R.J., Bryant A.S., Ohja B., et al. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg 80 (2005) 1207-1213
11. Cerfolio R.J., Bryant A.S., and Eloubeidi M.A. Routine mediastinoscopy and esophgeal ultrasound fine' needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative. Chest 130 (2006) 1791-1795
12. Sugarbaker D.J., Herndon J., Kohman L.J., Krasna M.J., and Green M.R. Results of cancer and leukemia group B protocol 8935. A multi institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 109 (1995) 473-485
13. Asamura H., Goya T., Koshiishi Y., et al. A Japanese Lung Cancer Registry Study. Prognosis of 13,010 resected lung cancers. J Thorac Oncol 3 (2008) 46-52
14. Pfannschmid J., Muley T., Bülzebruck H., et al. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 55 (2007) 371-377
15. Yang P., Allen M.S., Aubry M.C., et al. Clinical features of 5,628 primary lung cancer patients. Experience at Mayo clinic from 1997 to 2003. Chest 128 (2005) 452-462
16. Morgensztern D., Goodgame B., Baggstrom M.Q., et al. The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol 3 (2008) 135-139
17. Detterbeck F.C., and Socinski M.A. Induction therapy and surgery for I-IIIA B non-small cell lung cancer. In: Detterbeck F.C., Rivera M.P., Socinski M.A., and Rosenman J.G. (Eds). Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician vol. 19 (2001), W.B. Saunders, Philadelphia 267-282
18. Rusch V.W., Crowley J., Giroux D.J., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2 7 (2007) 603-612
19. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26 (2008) 3552-3559
20. Lim E., Harris G., Patel A., Adachi I., Edmonds L., and Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomised trials. J Thor Oncol 3 4 (2008) S56 abstract 150O
21. Stewart L.A., Burdett S., Tierney J.F., et al. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). J Clin Oncol 25 (2007) 397s abstr 7552
22. Le Péchoux C., Tribodet H., and Pignon J.P. Surgery (S) and radiotherapy (RT) plus adjuvant chemotherapy (CT) versus surgery and radiotherapy in non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs). J Clin Oncol 25 392s (2007) abstr 7521
23. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer (Cochrane Review). The Cochrane Library Issue 2 2005. Oxford: Update Software.
24. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
25. Lally B.E., Zelterman D., Colasanto J.M., et al. Postoperative radiotherapy for stage II or III nonsmall-cell lung cancer using the Surveillance Epidemiology and End Results Database. J Clin Oncol 24 (2006) 2998-3006
26. Radiation therapy in treating patients with non-small cell lung cancer that has been completely removed by surgery. (Clinical Trials.gov no NCT 00410683.) Bethesda MD: National library of Medicine 2009. Accessed January 2 2009 at http://www.clinicaltrials.gov/NCT 00410683.
27. Detterbeck F.C., and Jones D.R. Surgical treatment of stage IIIA (N2) non-small cell lung cancer. In: Detterbeck F.C., Rivera M.P., Socinski M.A., and Rosenman J.G. (Eds). Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician vol. 17 (2001), W.B. Saunders, Philadelphia 244-256
28. Martin J., Ginsberg R.J., Venkatraman E.S., et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 20 8 (2002) 1989-1995
29. Bueno R., Richards W., Swanson S., et al. Nodal stage after induction therapy for stage IIIA lung cancer determines survival. Ann Thorac Surg 70 (2000) 1826-1831
30. Jaklitsch M.T., Herndon J.E., DeCamp Jr. M.M., et al. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. J Surg Oncol 94 7 (2006) 599-606
31. Van Meerbeeck J.P., Kramer G., Van Schil P., et al. Induction chemotherapy (CT) in stage IIIA-N2 non-small cell lung cancer (NSCLC): an analysis of different regimens used in EORTC 08941. Lung Cancer 41 (2003) S(2 79, #, 273
32. Fleck J., Carmargo J., Godoy D., et al. Chemoradiation therapy (CRT) versus chemotherapy (CT) alone as a neoadjuvant treatment for stage III Non-small cell lung cancer (NSCLC). Preliminary report of a phase III prospective randomized trial. Proc ASCO (1993) Abstract 1108
33. Sauvaget J., Rebischung J., Vannetzel J., et al. Phase III study of neo-adjuvant MVP versus MVP plus chemo-radiation in stage III NSCLC. Proc ASCO 19 (2000) 495a Abstract 1935
34. Thomas M., Rube C., Hoffknecht P., et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 9 (2008) 636-648
35. Phase III randomized trial of preoperative chemotherapy versus preoperative concurrent chemotherapy and thoracic radiotherapy followed by surgical resection and consolidation chemotherapy in favorable prognosis patients with stage IIIA (N2) non-small cell lung cancer: RTOG 0412/SWOG S0332. Accessed January 2 2009 at http://www.rtog.org/members/protocols/0412/0412.pdf.
36. Preoperative chemotherapy versus concurrent chemoradiotherapy in N2 positive IIIA non small cell lung cancer (NSCLC). (Clinical Trials.gov no NCT 00452803.) Bethesda MD: National Library of Medicine 2009. Accessed January 2 2009 at http://www.clinicaltrials.gov/NCT 00452803.
37. Chemotherapy with or without radiation therapy before surgery in treating patients with stage IIIA non-small cell lung cancer. (Clinical Trials.gov no NCT00030771.) Bethesda MD: National Library of Medicine 2009. Accessed January 2 2009 at http://www.clinicaltrials.gov/NCT00030771.
38. Wagner Jr. H., Lad T., Piantadosi S., and Ruckdeschel J.C. Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin vinblastine and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881. Chest 106 6 Suppl. (1994) 348S-354S
39. Elias A., Skarin A., Leong T., et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 17 (1997) 147-161
40. Burdett S., Stewart L., Rydzewska, et al. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thor Oncol 1 (2006) 611-621
41. Berghmans T., Paesmans M., Meert A.P., et al. Survival improvement in resectable non-small-cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49 1 (2005) 13-23
42. Siegenthaler M., Pisters K., Merriman K., et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 71 (2001) 1105-1112
43. Martin J., Ginsberg R., Abolhoda A., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 72 (2001) 1149-1154
44. Roberts J.R., Eustis C., DeVore R.F., et al. Induction chemotherapy increases peri-operative complications in patients undergoing resection for non-small cell lung cancer. Ann Thorac Surg 72 (2001) 885-888
45. Perrot E., Guibert B., Mulsant P., et al. Preoperative chemotherapy does not increase complications after non-small cell lung cancer resection. Ann Thorac Surg 80 (2005) 423-427
46. Mansour Z., Kochetkova E.A., Ducrocq X., et al. Induction chemotherapy does not increase the operative risk of pneumonectomy. Eur J Cardiothorac Surg 31 (2007) 181-185
47. Uy K.L., Darling G., Xu W., et al. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg 134 (2007) 188-193
48. Lorent N., De Leyn P., Lievens Y., et al. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 15 (2004) 1645-1653
49. Betticher D., Schmitz S.H., Tötsch M., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21 (2003) 1752-1759
50. Garrido P., Gonzales-larriba J.L., Insa A., et al. Long term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1)-non-small cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 25 (2007) 4736-4742
51. Blackstock A.W., and Govindan R. Definitive chemoradiation for the treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 25 (2007) 4146-4152
52. Rolland E., Le Chevalier T., Auperin A., et al. Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): two meta-analyses using individual patient data (IPD) from randomised clinical trials (RCTs). J Thorac Oncol 2 8 (2007) S309-S310
53. Aupérin A., Le Péchoux C., Pignon J.P., et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1,764 patients. Ann Oncol 17 3 (2006) 473-483
54. NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311 (1995) 899-909
55. Aupérin A., Rolland E., Curran W.J., et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs). J Thorac Oncol 2 8 (2007) S310 abstract A1-05
56. Pfister D.G., Johnson D.H., and Azzoli C.G. American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22 (2004) 1-24
57. Zhao L., West B.T., Hayman J.A., et al. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 68 (2007) 103-110
58. Werner-Wasik M., Swann R.S., Bradley J., et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the radiation therapy oncology group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 70 2 (2008) 385-390
59. Van Meerbeeck J.P., Meersschout S., De Pauw R., Madani I., and De Neve W. Intensity modulated radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer. The Oncologist 13 (2008) 700-708
60. Vokes E.E., Herndon J.E., Kelley M.J., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: cancer and leukemia group B. J Clin Oncol 25 13 (2007) 1698-1704
61. Belani C.P., Wang W., Johnson D.H., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23 16 (2005) 3760-3767
62. Hanna N.H., Neubauer M., Yiannoutsos C., et al. Phase III Study of cisplatin etoposide and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26 (2008) 5755-5760
63. Kim M.K., Kim S., Choi E., et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): a randomized phase III trial. J Thorac Oncol 2 (2007) S308
64. Shepherd F.A., Johnston M.R., Payne D., et al. randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small cell lung cancer: a National cancer Institute of Canada Clinical Trials Group Study. Br J Cancer 78 5 (1998) 683-685
65. Wright G., Manser R.L., Byrnes G., Hart D., and Campbell D.A. Surgery for non-small cell lung cancer: systematic trials review and meta-analysis of randomised controlled. Thorax 61 (2006) 597-603
66. Johnstone D.W., Byhardt R.W., Ettinger D., et al. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Int J Radiat Oncol Biol Phys 54 (2002) 365-369
67. Stathopoulos G., Papakostas P., Malamos N.A., et al. Chemo-radiotherapy versus chemo-surgery in stage IIIA non-small cell lung cancer. Oncol Rep 3 (1996) 673-676
68. Taylor N.A., Liao Z.X., Cox J.D., et al. Equivalent outcome of patients with clinical stage IIIA non-small cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by resection. Int J Radiat Oncol Biol Phys 58 (2004) 204-212
69. Van Meerbeeck J.P., Kramer G.W.P.M., Van Schil P.E.Y., et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99 (2007) 442-450
70. Albain K.S., Swann R.S., Rusch V., et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer: outcomes update on North American Intergroup 0139. J Clin Oncol 23 16S (2005) 624
71. Neoadjuvant chemotherapy plus/minus surgery in non-small-cell lung cancer (NSCLC) stage IIIA/N2. (Clinical Trials.gov no NCT00273494.) Bethesda MD: National Library of Medicine 2009. Accessed January 2 2009 at http://www.clinicaltrials.gov/NCT00273494.
72. Paulson D.L. Selectivity in the surgical treatment of bronchogenic carcinoma. J Thorac Cardiovasc Surg 62 (1971) 554-562
73. van Tinteren Otto S., Hoekstra Egbert F., Smit, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359 (2002) 1388-1392
74. Tournoy K.G., De Ryck F., Vanwalleghem L.R., et al. Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial. Am J Respir Crit Care Med 177 5 (2008) 531-535
75. Ernst A., and Gangadharan S.P. A good case for a declining role for mediastinoscopy just got better. Am J Res Crit Care Med 177 (2008) 471-472
76. Assessment of surgical staging vs endoscopic ultrasound in lung cancer: a randomized clinical trial (ASTER Study). (Clinical Trials.gov no NCT00432640.) Bethesda MD: National Library of Medicine 2008. Accessed January 2 2009 at http://www.clinicaltrials.gov/NCT 00432640.
77. Vergeer M.R., Doornaert P., Leemans C.R., et al. Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation. Radiother Oncol 79 (2006) 39-44
78. Kelly K., Chansky K., Gaspar L.E., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26 (2008) 2450-2456
79. Blumenschein G.R., Moughan J., Curran W., et al. A phase II study of Cetuximab (C225) in combination with chemoradiation. J Thorac Oncol 2 8 (2007) S342
80. Socinski M.A., Morris D.E., Stinchcombe T.E., et al. Incorporation of bevacizumab and erlotinib with induction and concurrent carboplatin/paclitaxel and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer: preliminary report of a phase I/II trial. J Thorac Oncol 2 8 (2007) S447
81. Margaritora S., Cesario A., Galetta D., et al. An year experience with induction therapy in locally advanced nonsmall cell lung cancer (NSCLC): is clinical re-staging predictive of pathologic staging?. Eur J Cardiothorac Surg 19 (2001) 894-898
82. Vansteenkiste J.F., Stroobants S.G., Deleyn P.R., et al. Potential use of FDG-PET after induction chemotherapy in surgically staged IIIA-N2 non-small cell lung cancer. A prospective pilot study. Ann Oncol 9 (1998) 1193-1198
83. Hoekstra C.J., Stroobants S.G., Smit E.F., et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23 33 (2005) 8362-8370
84. Cerfolio R.J., Bryant A.S., and Ojha B. Restaging patients with N2 (stage IIIa) nonsmall cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. J Thorac Cardiovasc Surg 131 (2006) 1229-1235
85. De Leyn P., Stroobants S., De Wever W., et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group study. J Clin Oncol 24 (2006) 3333-3339
86. Varadarajulu S., and Eloubeidi M. Can endoscopic ultrasonography-guided fine-needle aspiration predict response to chemoradiation in non-small cell lung cancer?. Respiration 73 (2006) 213-220
87. Herth F.J.F., Annema J.T., Eberhardt R., et al. Endobronchial ultrasound with transbronchial needle aspiration for restaging the mediastinum in lung cancer. J Clin Oncol 26 (2008) 3346-3350
88. Pass H.I. Lung cancer staging techniques and induction therapy: maybe timing is everything. J Clin Oncol 28 (2008) 3306-3307
89. High-dose or standard-dose radiation therapy and chemotherapy in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be removed by surgery. (Clinical Trials.gov no NCT 00533949.) Bethesda MD: National Library of Medicine 2009. Accessed January 2 2009 at http://www.clinicaltrials.gov/NCT 00533949.
90. Yuan S., Sun X., Li M., et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 30 (2007) 239-244
91. Wei X., Liu H.H., Tucker S.L., et al. Risk factors for acute esophagitis in non-small cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformalk radiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 100-107
92. Yom S.S., Liao Z., Liu H.H., et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68 1 (2007) 94-102
93. De Ruysscher D., Wanders S., van Haren E., et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with nonsmall-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys 62 (2005) 988-994
94. Faria S.L., Menard S., Devic S., et al. Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. Int J Radiat Oncol Biol Phys 70 4 (2008) 1035-1038
95. Piet A.H., Lagerwaard F.J., Kunst P.W., et al. Can mediastinal nodal mobility explain the low yield rates for transbronchial needle aspiration without real-time imaging?. Chest 131 6 (2007) 1783-1787
96. Underberg R.W., van Sörnsen de Koste J.R., Lagerwaard F.J., et al. A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. Radiat Oncol 1 (2006) 8-12
97. Cox J., Chang J., Liao Z., et al. Acute esophageal reactions from proton beam therapy and concurrent chemotherapy for non-small cell lung cancer (NSCLC): Reduction in incidence and severity despite higher doses. J Thorac Oncol 2 8 (2007) S449 abstract PD4-16
98. Pisters K., Evans W.K., Azzolli C.G., et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for stages I-IIIA resectable non-small-cell lung. cancer guideline. J Clin Oncol 25 34 (2007) 5506-5518
99. National Collaborating Centre for Acute Care February 2005. Diagnosis and treatment of lung cancer. National Collaborating Centre for Acute Care London. Available from www.rcseng.ac.uk.
100. D'Addario G., Felip E., and on behalf of the ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis treatment and follow-up. Ann Oncol 19 Suppl. 2 (2008) ii39-ii40
101. NCCN clinical practice guidelines in oncology: non-small cell lung cancer.v.2.2009. Accessed January 2 2009 at http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
102. El Sharouni S.Y., Kal H.B., and Battermann J.J. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 89 December (12) (2003) 2184-2189